Fate Therapeutics (FATE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cell Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 15.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.56% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
- Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
- Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
- Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
- Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Rethinking Irgarol toxicity: a unified framework linking environmental fate, bioactivity, and human exposure. — Environ Sci Pollut Res Int 2026 Oct 10 PMID 42859357
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Fate Therapeutics.
Full FATE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.